Molecular Vision: Querques, Mol Vis 2014; 20:575-592. Table 2

Table 2. Changes in mean measurements and in specific features in patients with Best vitelliform macular dystrophy.

Mean measurements and specific features	Study entry	Last visit (41.14±18.5 months)	P(1)	P(2)	P(3)
BCVA (LogMAR)	0.34±0.34	0.32±0.33	0.2		-
Overall lesion area (mm²)	6.62±4.9	7.34±6.1	0.05	0.03	0.04
Hyperautofluorescent component of the lesion (mm²)	4.10±3.7	4.16±3.7	0.3	0.06	0.05
Hypoautofluorescent component of the lesion (mm²)	2.94±2.7	3.20±2.8	0.7	0.07	0.06
FAF fovea (n)	Hypo=29 / Hyper=3 / Iso=10	Hypo=29 / Hyper=3 / Iso=10	-	0.7	0.7
EZ status fovea (n)	Normal=15 / Disrupted=14/ Absent=13	Normal=13 / Disrupted=16 /Absent=13	-	<0.001	<0.001
OCT reflectivity (n)	Mixed=22 / Hyper=12 / Hypo=3	Mixed=22 / Hyper=12 / Hypo=3	-	0.2	0.4
Maximal OCT lesion thickness (μm)	299.87±187.8	315.21±161.0	0.5	0.03	0.03
Maximal OCT lesion width (μm)	2503.41±975.0	2546.07±1125.2	0.1	0.4	0.6
OCT neurosensory retinal thickness fovea (μm)	89.25±28.5	90.85±40.9	0.9	0.03	0.02
CMT (μm)	341.08±178.5	351.17±156.7	0.8	0.1	0.2

BCVA: best-corrected visual acuity; CMT: central macular thickness; FAF: fundus autofluorescence; EZ: Ellipsoid Zone; LogMAR: logarithm of the minimal angle of resolution; n: number of eyes; OCT: optical coherence tomography; RPE: retinal pigment epithelium; P (1) statistical significance of change between baseline and last visit; P (2) statistical significance of correlation with BCVA at baseline; P (3) statistical significance of correlation with BCVA at last follow up visit.